Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-DG prophylaxis for rhinovirus in healthy volunteers
NCT06375772Phase 2Terminated
- Sponsor
- G.ST Antivirals
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 2-deoxy-d-glucose in acute nasopharyngitis, sponsored by G.ST Antivirals. Primary endpoint: Difference in the rate of rhinovirus-associated illness between 2-DG and placebo at Day 22. Started Apr 2024; status: terminated.
02
Drugs
2-deoxy-d-glucose
03
Conditions
acute nasopharyngitis
Beyond the preview
Go deeper on NCT06375772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375772.